Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
| Revenue (Most Recent Fiscal Year) | $117.00M |
| Net Income (Most Recent Fiscal Year) | $-307.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -257.27% |
| Net Margin (Trailing 12 Months) | -262.39% |
| Return on Equity (Trailing 12 Months) | -57.17% |
| Return on Assets (Trailing 12 Months) | -25.80% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.17 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.15 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 90.86M |
| Free Float | 78.33M |
| Market Capitalization | $1.48B |
| Average Volume (Last 20 Days) | 0.56M |
| Beta (Past 60 Months) | 0.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 13.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |